Prof Biswajit Dhar (in The Leaflet, 16 April 2025) argues that the major flexibilities in the Indian Patent Act – Section 3(d) and the compulsory licensing system – to make medicines affordable, have been under-implemented. As prices of medicines have skyrocketed, secondary patenting has proliferated while compulsory licensing has been invoked only once.
In full here.
Leave a Reply